Nicotinic receptors have been implicated in a broad range of neurological disorders, including autism, and increasing the activation of nicotinic receptors could be beneficial to affected individuals. A molecule that regulates the receptor activity by binding to the receptor away from its active site, called an allosteric modulator, could lead to a new class of drugs to treat these disorders. This project explores a molecule with that potential, the natural product d-formylflustrabomide (dFBr). The interaction between dFBr and the nicotinic receptor will be characterized and dFBr will be used as a template to search for other molecules that may also specifically regulate nicotinic receptors. The goal of this study is to develop the natural product into a more usable form with increased potency and less potential side effects. Since this is a new type of drug, it may open up new avenues for understanding and treating autism spectrum disorders.